Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Midatech Pharma adds partner to US marketing drive

Wednesday, September 21, 2016 0:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Midatech Pharma Plc (LON:MTPH NASDAQ: MTP)  has teamed up with distributor R-Pharm to promote chemotherapy side effect treatment Zuplenz and oral thrush drug Oravig in the US. 

R-Pharm will market the Midatech drugs to  potential new customers and give additional  promotion in existing accounts. 

Mark Pavoa, R-Pharm US’s chief executive,  said: “Zuplenz and Oravig are complementary to our oncology franchise, which includes Ixempra.

“Cancer patients and treatment teams face many challenges as they battle the disease, and we are proud to represent these two additional potential solutions.” 

Zuplenz is an oral soluble film formulation of the 5-HT3 receptor antagonist ondansetron that can prevent the nausea and vomiting associated chemotherapy and radiotherapy.

Oravig is the only once-daily local therapy available for treatment of oral thrush in adults.

Midatech acquired Nasdaq-listed Dara at the end of 2015 to give it a US distribution network to market its range of products to help  patients undergoing cancer treatment.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.